Navigation Links
Colgate Announces 11% Dividend Increase Effective 2nd Quarter 2008
Date:2/27/2008

NEW YORK, Feb. 27, 2008 /PRNewswire-FirstCall/ -- Reflecting the Company's positive outlook, the Board of Directors of Colgate-Palmolive Company today increased the ongoing quarterly common stock cash dividend by 11%. The increase will be effective as of second quarter 2008. The new quarterly rate of $.40 per share is up from $.36. The Board declared that the second quarter dividend is to be paid on May 15, 2008 to shareholders of record as of April 24, 2008. On an annualized basis, the new dividend rate is $1.60 vs. $1.44 per share previously.

Ian Cook Colgate President and CEO, said: "This dividend increase demonstrates the Board's confidence in the continued strong and profitable growth of Colgate's global business, our cash generation capabilities, and our firm commitment to building value."

* * *

About Colgate-Palmolive: Colgate-Palmolive is a leading global consumer products company, tightly focused on Oral Care, Personal Care, Home Care and Pet Nutrition. Colgate sells its products in over 200 countries and territories around the world under such internationally recognized brand names as Colgate, Palmolive, Mennen, Softsoap, Irish Spring, Protex, Sorriso, Kolynos, Elmex, Tom's of Maine, Ajax, Axion, Soupline, and Suavitel, as well as Hill's Science Diet and Hill's Prescription Diet. For more information about Colgate's global business, visit the Company's web site at http://www.colgate.com.


'/>"/>
SOURCE Colgate-Palmolive
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. AUDIO from Medialink and Colgate: A Healthy Smile - Not Just a Question for Your Dentist
2. "High School Musicals" Corbin Bleu Joins Colgate-Palmolive, United Way and Miami-Dade Elementary School Students for Dental Health Challenge
3. Colgate Declares Regular Quarterly Dividends
4. Colgate-Palmolive Partners With the National Breast Cancer Foundation to Provide Education and Free Mammograms
5. Versus Technology Announces First Quarter Results
6. AMA Foundation Announces Seed Grant Research Recipients
7. Crdentia Announces Completion of $10.2 Million Long-Term Debt Financing
8. Kendle Delivers Strong Growth in Revenues, New Business Authorizations and Operating Margin for Full-Year 2007; Announces Guidance for 2008
9. QED International Associates Announces Changes to the HealthShares(TM) GI/Gender Health Index
10. Medarex Announces 2007 Fourth Quarter and Year End Financial Results
11. Grupo Casa Saba Announces Fourth Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...s the Latest Developments in Molecular,Testing and... /PRNewswire-USNewswire/ -- The practice of,pathol...g and the promise,of personalized medicine will ch...and other imaging technologies will change the way...ogists is taking a leadership role in,making sure ...
(Date:9/5/2008)...RNewswire-USNewswire/ -- The Health Resources,and ... million in grants to,increase and improve medical... grants continue President Bush,s historic expansi...w reach more economically,vulnerable and geographi...dministrator Elizabeth M. Duke said. "In 2007, mor...
(Date:9/5/2008)...tical ,anti-cloak, could bring objects out of hidi...-- Just in case someone develops a cloak of invisi... how to uncloak the objects it hides. , Accordi...in materials underneath an invisibility cloak woul...esearchers at Shanghai Jiao Tong University in Chi...
(Date:9/5/2008)...ain to commit to develop a National AIDS,Strategy ...p. 5 /PRNewswire-USNewswire/ -- The,Republican Nat...ion of the,domestic AIDS epidemic in the United St...erseas. Neither Presidential nominee Sen. John McC... mentioned AIDS in their remarks,to Convention del...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 3
...ndenses the blood and increases the risk of heart ...versity of Texas, it has been found that too many ... - in Britain. He believes that cold temperatures ...s thicker than normal. This raises the risk of clo...
...ecognised an amino-acid taste receptor.Dr Charles ... and the University of California, San Diego, repo... can identify five different tastes — bitter, salt...ur associated with monosodium glutamate (MSG).Rece...
...ke and have a history of alcohol problems have poo...most 400 patients// to find if there was a link be...ified them into four groups:current tobacco use on...th, or neither. The patients with both current to...
... that an air pollutant emitted by power plants and...ng can increase your chances of dying from lung ca...icles of air pollution. The study authors contend ...you to "fine particulate matter" that makes its wa...
Other Medicine News:Health News:Comprehension of taste receptor, 2
(Date:9/3/2008)...- Simcere,Pharmaceutical Gr...lier of,branded generic pharmaceuticals and manufa... Endu (also known as Endostar) in China,announced...dy., At the request of the SFDA, Simcere initiate...e safety and therapeutic efficacy of Endu, a modif...
(Date:9/3/2008)...EVA, Sept. 3 /- Artelis SA and,Selexi...monoclonal antibody,production with the achievemen...er. This record level was accomplished by applying...rformance stable Selexis CHO,production cell line ...t,Selexis SA using their proprietary Selexis Genet...
(Date:9/3/2008)...s, Updates Zingo Launch Progress and Adlea ... Conference Call Today at 11:30 am ET, SOUTH...all/ -- Anesiva,Inc. (Nasdaq: ANSV ) announced t...to focus on commercial and late-stage product deve...y pharmaceutical pain management,company. The comp...
(Date:9/2/2008)...wire-FirstCall/ -- Forest Laboratories, Inc.,(NYSE...ounced results from,two global Phase III studies o...anticholinergic for the treatment of patients with...both the ACCLAIM/COPD I&II,(AClidinium CLinical Tr...evere COPD Patients) studies, once-daily aclidiniu...
Breaking Medicine Technology:Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 2Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 3Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 2Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 3Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 5Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 2Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 3Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 4Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 5Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 6Climate change has major impact on oceans 2245 1Climate change has major impact on oceans 2245 2Climate change has major impact on oceans 2245 3Climate change has major impact on oceans 2245 4Large changes needed to address global obesity epidemic 12109 1Large changes needed to address global obesity epidemic 12109 2Symposium on drug resistant diseases set for annual AAAS conference 12105 1MIT professor to discuss future of biofuels 2238 1MIT professor to discuss future of biofuels 2238 2
..., 2007 - CombinatoRx,Incorporated (NASDAQ: CRXX),...inded, placebo-controlled phase 2 clinical trials ...d rheumatoid,arthritis (RA) will be featured at th...l Congress of Rheumatology meeting, June,13-16, 20...Satellite Symposium, Room 111, Thursday, June 14, ...
...Waltham, Mass., June 7, 2007 – Dynogen Pharm...randomized, double-blind,placebo-controlled Phase...sease (GERD). The study was designed to demonstra...nocturnal GERD,(NGERD). The 0.5 mg dose of DDP73...n the primary endpoint of reduction in,the number ...
Other Medicine Technology:Novel Mechanism Insights and Additional Data on CombinatoRx Drug,Candidates to Be Presented at Upcoming EULAR Meeting 2Novel Mechanism Insights and Additional Data on CombinatoRx Drug,Candidates to Be Presented at Upcoming EULAR Meeting 3Dynogen's DDP733 Reduces Reflux in Phase 1b GERD Study 2Dynogen's DDP733 Reduces Reflux in Phase 1b GERD Study 3
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
Medicine Products: